Your drug's
begins here.

Enlisting an integrated suite of
cutting-edge preclinical tools
to direct clinical development.

Learn More
  • Leading patient engagement and mobile care management solution and precision...READ MORE >
  • Collaboration to provide expanded use of Paradigm Cancer Diagnostic (PCDx&tr...READ MORE >
  • Responsibility for Pancreatic Cancer Research Team Moves to Seattle Non-...READ MORE >
  • TD2 and Inform Genomics Announce Strategic Partnership
    <...READ MORE >

Paradigm and TD2 Announce Strategic Partnership For Tumor Profiling Service

Collaboration to provide expanded use of Paradigm Cancer Diagnostic (PCDx™) service by oncologists across large oncology network

SCOTTSDALE, AZ and ANN ARBOR, MI Monday, April 20, 2015 -- Paradigm and Translational Drug Development (TD2) today announced a partnership under which Paradigm will provide their PCDx test to TD2’s affiliated oncology provider networks.

PCDx is a Next-Generation Sequencing (NGS) based diagnostic test that is designed to provide physicians and patients with a more targeted, personalized approach to cancer treatment by identifying the underlying genomic and proteomic alterations of a patients tumor’s DNA, RNA & Protein.  The service is unique as the only commercially available NGS-based assay that interrogates DNA mutations, copy number variations, gene fusions and messenger RNA expression (mRNA) in typically less than five business days.

This collaboration with Paradigm will provide oncologists in the TD2 networks access to this cutting edge technology and make possible more informed and individually tailored treatment strategies for patients.

Click here for full press release.